The form is not published.

Heading

2025 Impact Round-Up: Turning Belief into Progress for Follicular Lymphoma

2025 Impact Round-Up: Turning Belief into Progress for Follicular Lymphoma

In 2025 the FLF accelerated scientific momentum, strengthened global collaboration, and elevated the patient voice. In her first year as ...
/
Updates from the 2025 American Society of Hematology (ASH) Annual Meeting

Updates from the 2025 American Society of Hematology (ASH) Annual Meeting

The Follicular Lymphoma Foundation at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, one of the world’s ...
/
Vikki's Story

Vikki’s Story

I remember everything about the day I was diagnosed with FL. And I remember my husband crying for the first ...
/
Epcoritamab-bysp in Combination with Rituximab and Lenalidomide Approved as Treatment Option for Relapsed or Refractory Follicular Lymphoma in the U.S.

Epcoritamab-bysp in Combination with Rituximab and Lenalidomide Approved as Treatment Option for Relapsed or Refractory Follicular Lymphoma in the U.S.

On November 18, 2025, the FDA approved epcoritamab-bysp (EPKINLY®) in combination with rituximab and lenalidomide for adults with relapsed or ...
/
Unlock the Cure Gala 2025 Raises Funds for Vital Research

Unlock the Cure Gala 2025 Raises Funds for Vital Research

The Unlock the Cure Gala 2025 brought supporters together to fund vital research and deliver hope for people living with ...
/
Choosing Your Next Treatment: What FL (follicular lymphoma) Patients Should Know

Choosing Your Next Treatment: What FL (follicular lymphoma) Patients Should Know

Watch this webinar from November 2025 where the panel discusses and shares insights on what matters most to doctors and ...
/